Lexeo Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

LXEO$3.06-2.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss (unaudited)

Condensed Statements of Operations and Comprehensive Loss

(Unaudited, in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Operating expenses
Research and development	$23,423	$17,246	$55,725	$44,920
General and administrative	8,120	3,027	22,659	8,619
Total operating expenses	31,543	20,273	78,384	53,539
Operating loss	(31,543)	(20,273)	(78,384)	(53,539)
Other income and expense
Loss on fair value adjustment to convertible SAFE Note	-	(272)	-	(272)
Other income (expense), net	(3)	1	(9)	(6)
Interest expense	(35)	(52)	(107)	(155)
Interest income	2,092	488	6,091	1,765
Total other income and expense	2,054	165	5,975	1,332
Loss from operations before income taxes	(29,489)	(20,108)	(72,409)	(52,207)
Income taxes	-	-	-	-
Net loss and comprehensive loss	$(29,489)	$(20,108)	$(72,409)	$(52,207)
Net loss per common share, basic and diluted	$(0.89)	$(12.36)	$(2.31)	$(32.24)
Weighted average number of shares outstanding used in computation of net loss per common share, basic and diluted	33,063,153	1,626,734	31,354,821	1,619,152

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.